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Background: Hydralazine and isosorbide dinitrate (HISDN) has been shown to further reduce mortality in black patients with systolic heart failure 
(SHF) when added to a background of approved heart failure therapies. To date no study has evaluated the role of HISDN in blacks and non-blacks 
(NB) with diastolic heart failure (DHF).
Methods: Retrospectively, we examined all patients admitted and followed at the Montefiore Medical Center over the last 10 years with a 
diagnosis of DHF or heart failure and ejection fraction > 50%. We compared one-year mortality rates between subgroups by self-identified race 
(when available) in those who received HISDN and those who did not.
Results: 1,141 (949 Black, 634 NB) and 15,565 (5,004 Black, 6,500 NB) subjects comprised the HISDN-treated and untreated cohorts, 
respectively. One-year mortality rate was 15.9% in the black-treated group and 20.8% in the black-untreated group (p = 0.0004). Furthermore, 
HISDN provided a survival benefit for NB subjects (Figure; p < 0.0001).
Conclusions: Beyond the benefit of HISDN observed in blacks with SHF, our data suggest that HISDN decreases mortality in both black and NB 
patients with DHF.
